Description

Celyad Oncology S.A., a clinical-stage biopharmaceutical company headquartered in Mont-Saint-Guibert, Belgium, specializes in the discovery and development of innovative chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its pipeline includes several key candidates: CYAD-101, an allogeneic CAR-T, is currently undergoing a Phase 1b clinical trial for metastatic colorectal cancer. For relapsed/refractory multiple myeloma, the company is evaluating CYAD-211, an shRNA-based allogeneic CAR-T candidate, in a Phase 1 study. Additionally, CYAD-02, an autologous CAR-T, is in Phase 1 clinical trials for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical stage, CYAD-203 represents a non-gene edited allogeneic CAR-T designed to co-express interleukin-18 and natural killer group 2D ligands, targeting solid tumors. To support its efforts, Celyad Oncology holds a licensing agreement with Novartis International AG regarding United States patents for allogeneic CAR-T cells. It also maintains a research and development collaboration and licensing agreement with Horizon Discovery Group plc, leveraging their shRNA technology to develop a second non-gene-edited allogeneic platform. Founded in 2004 as Celyad SA, the company adopted its current name in June 2020.